Skip to main content
Figure 1 | BMC Medicine

Figure 1

From: Immunogenicity and safety of concomitant administration of a measles, mumps and rubella vaccine (M-M-RvaxPro®) and a varicella vaccine (VARIVAX®) by intramuscular or subcutaneous routes at separate injection sites: a randomised clinical trial

Figure 1

Reverse cumulative distribution curve of antibody concentrations for (a) measles, (b) mumps, (c) rubella and (d) varicella at 42 days post-vaccination for children initially seronegative to measles, mumps, rubella or varicella in the antigen-specific per-protocol sets. (IM group, both vaccines administered by the intramuscular route; SC group, both vaccines administered by the subcutaneous route).

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us